SynthesisBMC pediatrics2025
The diagnostic accuracy of MMP-7 for the diagnosis for biliary atresia- a systematic review and meta-analysis.
Synthesis in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biliary atresia-related liver fibrosis.Frontiers in cell and developmental biology · 2026Review
- Serum matrix metalloproteinase-7 as a diagnostic and prognostic biomarker in primary biliary cholangitis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMatrix metalloproteinase-7 (MMP-7) has emerged as a promising biomarker for the early detection of biliary atresia (BA), with potential to significantly improve diagnostic accuracy and patient outcomes. This meta-analysis evaluated the diagnostic performance of MMP-7 to determine its clinical utility in the identification of BA.
methodsA comprehensive literature search was performed in PubMed, Embase, Web of Science, and the Cochrane Library for studies published through March 21, 2024. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Diagnostic parameters including sensitivity, specificity, likelihood ratios, and diagnostic odds ratios were pooled. Summary receiver operating characteristic curves were constructed to evaluate overall diagnostic performance.
results9 studies comprising 710 patients were included in the analysis. MMP-7 demonstrated a pooled sensitivity of 0.80 (95% CI: 0.58-0.92) and specificity of 0.97 (95% CI: 0.90-0.99), with an area under the curve of 0.97 (95% CI: 0.95-0.98). Subgroup analyses by geographic sample size, study type and mean/median age revealed no significant differences in diagnostic performance. An inverse relationship was observed between cutoff values and sensitivity, with higher thresholds yielding lower sensitivity but improved specificity.
conclusionThe sensitivity of MMP-7 is influenced by sample processing methods, sample handling time, and substantial variability in cutoff values. Therefore, it cannot serve as an independent diagnostic tool for BA, and BA diagnosis should continue to rely on the gold standard. However, MMP-7 may serve as a valuable tool for risk stratification in BA. Future research should investigate the diagnostic performance of MMP-7 across varying cutoff values, reflecting the observed variability across studies. PROSPERO REGISTRATION NUMBER: CRD42024532998.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.